文献速递免疫规划妇幼与学校卫生

使用传统血清学方法和口腔液体评估2-16岁儿童连续年度接种LAIV后的免疫原性

Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV.
PubMed 文献 · Vaccine · 2020-02-15

英国在2014/15至2016/17三个连续年度对254、249和162名2-16岁儿童开展III/IV期开放标签研究,评估年度接种四价减毒活流感疫苗(qLAIV)的免疫原性。结果显示各年度抗体应答均较差,口腔液体(OF)检测与血凝抑制(HAI)结果一致,且既往接种AS03B佐剂甲型H1N1pdm09疫苗对后续qLAIV接种后的抗体水平有持续影响。

要点

  • 三个年度qLAIV接种后血清HAI抗体滴度升高有限,血清转化率最高为39%-43%(乙型流感)和40%(H3N2)。
  • 口腔液体标本采集率(96%)高于配对血清(87%),其检测结果与HAI一致,特异性88.1%和71.6%,敏感性86.4%和74.8%。
  • 既往接种AS03B佐剂甲型H1N1pdm09疫苗导致所有三个年度接种前后A(H1N1)pdm09 HAI滴度更高、NAI滴度更低。

核心结论

  • 三个研究年度中,接种qLAIV均导致较差的抗体应答;口腔液体是可自行采样的替代标本类型,易于从儿童获取,其分析得出与经典HAI血清学相似的结论。
  • 作者建议应研究口腔液体用于血清阳性率研究的适用性;并证明既往接种AS03B佐剂甲型H1N1pdm09疫苗有持续效应,即使重复接种qLAIV后仍存在,表明早期暴露于流感抗原具有显著持久效应。

研究设计与样本

  • III/IV期开放标签研究,在2014/15至2016/17三个连续年度分别纳入254、249和162名儿童,评估年度接种qLAIV(Fluenz™)的免疫原性。
  • 采用血凝抑制(HAI)和抗A(H1N1)pdm09神经氨酸酶(NAI)试验检测血清应答,并按2009/10年度是否接种AS03B佐剂甲型H1N1pdm09大流行疫苗进行分层。
  • 使用ELISA探索口腔液体中针对A(H1N1)pdm09和H3N2疫苗组分的抗体水平。

主要发现

  • 获得的配对接种前后口腔液体标本(96%)多于配对血清(87%)。
  • HAI试验的几何平均滴度升高有限,第一年两种乙型流感毒株血清转化率分别为39%(95%CI 33-46%)和43%(95%CI 36-50%),第二年H3N2血清转化率为40%(95%CI 33-46%)。
  • 既往接种大流行疫苗导致所有三个年度接种前后A(H1N1)pdm09 HAI滴度更高、NAI(N1神经氨酸酶)滴度更低。
  • 口腔液体结果与HAI结果一致;与HAI相比,A(H1N1)pdm09和H3N2的检测特异性分别为88.1%和71.6%,敏感性分别为86.4%和74.8%。

临床怎么用

  • 作者认为口腔液体是可自行采样的替代标本类型,易于从儿童获取,其分析得出与经典HAI血清学相似的结论。
  • 作者建议应研究口腔液体用于血清阳性率研究的适用性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The UK introduced quadrivalent live attenuated influenza vaccine (qLAIV) for children in 2013/2014. The impact of annual vaccination on effectiveness and immunogenicity is being assessed. METHOD: A phase III/IV open-label study of the immunogenicity of annual vaccination with qLAIV (Fluenz™) was conducted over three consecutive years (2014/15-2016/17) in 254, 249 and 162 children respectively. Serum responses to vaccine components were measured by Haemagglutination Inhibition (HAI) and anti-A(H1N1)pdm09 Neuraminidase (NAI) assays, stratified according to previous receipt of AS03B-adjuvanted A(H1N1)pdm09 pandemic vaccine in 2009/10. Antibody levels to the A(H1N1)pdm09 and H3N2 vaccine components in oral fluids (OF) were explored using an ELISA. FINDINGS: More paired pre- and post-vaccination oral fluids (96%) than paired sera (87%) were obtained. Geometric mean titre rises using HAI assays were limited, with maximum rises seen in year one for both influenza B strains when 39% and 43% of subjects seroconverted (95% confidence interval 33-46% and 36-50%, respectively) and year two for influenza H3N2, when 40% (33-46%) individuals seroconverted. Prior pandemic vaccine receipt resulted in higher pre- and post-vaccination A(H1N1)pdm09 HAI titres and lower pre-and post-vaccination NAI (N1 neuraminidase) titres in all three years. OF results were congruent with HAI results; assay specificity compared to HAI was 88.1 and 71.6 percent, and sensitivity was 86.4 and 74.8 percent respectively for A(H1N1)pdm09 and H3N2. CONCLUSION: In all three study years, vaccination with qLAIV resulted in poor antibody responses. However, OFs are an alternative specimen type that allows self sampling, can easily be obtained from children, and their analysis leads to similar conclusions as classic serology by HAI. Their suitability for seroprevalence studies should be investigated. We demonstrated a sustained effect from prior receipt of the AS03B-adjuvanted A(H1N1)pdm09 vaccine, even after repeat vaccination with qLAIV indicating that early exposure to influenza antigens has a significant long lasting effect.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hoschler K, Maharjan S, Whitaker H, et al. Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV. Vaccine. 2020. PMID: 32070679. doi:10.1016/j.vaccine.2020.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。